Berners-Price S J, Mirabelli C K, Johnson R K, Mattern M R, McCabe F L, Faucette L F, Sung C M, Mong S M, Sadler P J, Crooke S T
Cancer Res. 1986 Nov;46(11):5486-93.
We have previously reported the cytotoxicity and antitumor activity of bis(diphenylphosphino)ethane (DPPE) and a variety of its transition metal complexes. During studies of the chemistry of a gold complex of this group [(AuCl)2(DPPE)], it was observed that this complex readily underwent ring closure on reaction with DPPE to form the tetrahedral complex [Au(DPPE)2]+. Various counterion forms (e.g., Cl-) of this cation were isolated and were found to exhibit a remarkably high stability in solution. Evaluation of [Au(DPPE)2]Cl in mice bearing i.p. P388 leukemia demonstrated that the compound produced an average of 87% increase in life span at its maximally tolerated dose (2-3 mumol/kg/day for 5 days). Activity was also seen in i.p. M5076 reticulum cell sarcoma (60% increase in life span) and s.c. mammary adenocarcinoma 16/c. Modest activity was evident in i.p. B16 melanoma and L1210 leukemia. A subline of P388 leukemia resistant to cisplatin was not cross-resistant to [Au(DPPE)2]Cl. In addition, combination therapy of [Au(DPPE)2]Cl and cisplatin against i.p. P388 demonstrated an advantage over single-agent therapy. In vitro studies of [Au(DPPE)2]Cl showed that the compound: is cytotoxic to tumor cell lines; is only minimally inhibited in its cytotoxic activity by the presence of serum; produces DNA protein cross-links and DNA strand breaks in cells; and inhibits macromolecular synthesis with a preferential inhibitory effect on protein synthesis relative to DNA and RNA synthesis. 31P nuclear magnetic resonance spectroscopy indicated that the compound is stable in the presence of serum proteins, thiols, or disulfides and that it reacts with Cu(II) resulting in the formation of a Cu(I)DPPE complex. The results of these in vivo and in vitro experiments suggest that the contrasting pharmacological profile of [Au(DPPE)2]Cl with respect to other gold(I) phosphine complexes may be related to both the kinetic stability of the complex and its stability in the presence of thiols.
我们之前报道过双(二苯基膦基)乙烷(DPPE)及其多种过渡金属配合物的细胞毒性和抗肿瘤活性。在研究该类金配合物[(AuCl)2(DPPE)]的化学性质时,观察到该配合物与DPPE反应时容易发生闭环反应,形成四面体配合物[Au(DPPE)2]+。分离出了该阳离子的各种抗衡离子形式(如Cl-),并发现它们在溶液中表现出非常高的稳定性。对荷瘤小鼠腹腔注射P388白血病模型进行[Au(DPPE)2]Cl的评估表明,该化合物在其最大耐受剂量(2 - 3 μmol/kg/天,持续5天)时平均使寿命延长87%。在腹腔注射M5076网状细胞肉瘤(寿命延长60%)和皮下接种乳腺腺癌16/c模型中也观察到了活性。在腹腔注射B16黑色素瘤和L1210白血病模型中也有适度活性。对顺铂耐药的P388白血病亚系对[Au(DPPE)2]Cl无交叉耐药性。此外,[Au(DPPE)2]Cl与顺铂联合治疗腹腔注射P388白血病显示出比单药治疗更具优势。[Au(DPPE)2]Cl的体外研究表明,该化合物:对肿瘤细胞系具有细胞毒性;血清的存在对其细胞毒性活性仅有轻微抑制;在细胞中产生DNA - 蛋白质交联和DNA链断裂;抑制大分子合成,相对于DNA和RNA合成,对蛋白质合成具有优先抑制作用。31P核磁共振光谱表明,该化合物在血清蛋白、硫醇或二硫化物存在下稳定,并且它与Cu(II)反应形成Cu(I) - DPPE配合物。这些体内和体外实验结果表明,[Au(DPPE)2]Cl与其他金(I)膦配合物相比具有不同的药理学特征,这可能与该配合物的动力学稳定性及其在硫醇存在下的稳定性有关。